Project Grant R01HL183169
Award Date 9/1/26
Completion Date 5/31/30
Dollars Obligated $802K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
- The National Institutes of Health National Heart Lung and Blood Institute awarded The General Hospital Corporation (Massachusetts General Hospital) $186,840 under CFDA 93.837 Cardiovascular Diseases Research on July 3, 2026, for advanced analysis of high-resolution cardiac diffusion tensor imaging (DTI). The funded work develops and applies DTI phenomapping, a voxel-level quantitative analysis approach for cardiac magnetic resonance imaging that resolves distinct microstructural patterns in...
- The National Heart Lung and Blood Institute awarded The General Hospital Corporation (Massachusetts General Hospital) $867,656 under the Cardiovascular Diseases Research program (CFDA 93.837) on May 1, 2026, to develop and apply comparative effectiveness evidence methods for evaluating medical therapies in heart failure with mildly reduced ejection fraction (HFMREF). The award funds completion of the largest echocardiography registry in the world and application of regression discontinuity...
- The National Institutes of Health National Heart Lung and Blood Institute awarded The General Hospital Corporation (Massachusetts General Hospital) $121,345 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 15, 2026. The award funds development of positron emission tomography (PET) imaging of oxidized collagen as a biomarker for myocardial fibrosis in heart failure with preserved ejection fraction (HFpEF). The project focuses on targeted PET imaging probes that bind...
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $391,700 under the Cardiovascular Diseases Research program (CFDA 93.837) on February 15, 2026. The award funds mixed-methods health services research to optimize the regionalization of care for acute type A aortic dissection (ATAAD) and increase appropriate interfacility transfer of ATAAD patients from low-volume to high-volume aortic centers. The research...
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $736,411 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of neutrophil-derived resistin-like molecule G (RELMG) in arrhythmia pathogenesis and prevention. The research examines RELMG's mechanism of action and therapeutic potential in reducing ventricular tachycardia and atrial fibrillation following...
- The National Heart, Lung, and Blood Institute awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $614,843 on May 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research examining the relationship between indexed exercise blood pressure and adverse vascular and ventricular remodeling as risk factors for heart failure with preserved ejection fraction (HFPEF). The research investigates whether the ratio of peak...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Massachusetts General Hospital a $247,500 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) effective September 1, 2025 through August 31, 2027. The award supports research to develop a non-invasive biomarker-based classifier model for early detection of pulmonary vascular dysfunction (PVD) in acute respiratory distress syndrome (ARDS) patients. ARDS patients with PVD...
- The National Heart, Lung, and Blood Institute awarded Massachusetts General Hospital $747,256 under Cardiovascular Diseases Research (CFDA 93.837) on August 17, 2026, to investigate the role of METTL3 (a methyltransferase enzyme) in heart failure with preserved ejection fraction (HFpEF). The project addresses an unmet clinical need: no pharmacological therapy has been proven to improve survival in HFpEF, the most prevalent form of heart failure particularly among patients with metabolic...
- Federal Project Grant Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Massachusetts General Hospital $247,500 under the Cardiovascular Diseases Research program (CFDA 93.837) to validate a positron emission tomography (PET) imaging probe targeting CD206-positive macrophages for idiopathic pulmonary fibrosis (IPF) diagnosis and monitoring. The project, which commenced August 15, 2025 and concludes July 31, 2027, aims to develop and validate a PET imaging agent that shares...
- The National Heart Lung and Blood Institute awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $330,176 on September 25, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct mentored research on the effect of severe obesity on regional lung perfusion in acute hypoxemic respiratory failure. The award funds two primary research aims. Aim 1 defines the association between severe obesity and regional lung perfusion in a novel...